Host resistance to visceral leishmaniasis: prevalence and prevention

References

• Kaye P, Scott P. Leishmaniasis: complexity at the host-pathogen interface. Nat Rev Microbiol. 2011;9(8):604–615.
   PubMed Web of Science ®Google Scholar
• McCall LI, Zhang WW, Matlashewski G. Determinants for the development of visceral leishmaniasis disease. PLoS Pathog. 2013;9(1):e1003053.
   PubMedGoogle Scholar
• Khadem F, Uzonna JE. Immunity to visceral leishmaniasis: implications for immunotherapy. Future Microbiol. 2014;9(7):901–915.
   PubMed Web of Science ®Google Scholar
• McGwire BS, Satoskar AR. Leishmaniasis: clinical syndromes and treatment. QJM. 2014 Jan;107(1):7–14.
   PubMed Web of Science ®Google Scholar
• Kumar R, Nylén S. Immunobiology of visceral leishmaniasis. Front Immunol. 2012 Aug 14;3:251.
   PubMed Web of Science ®Google Scholar
• Ready PD. Epidemiology of visceral leishmaniasis. Clin Epidemiol. 2014 May 3;6:147–154.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay D, Dalton JE, Kaye PM, et al. Post kala-azar dermal leishmaniasis: an unresolved mystery. Trends Parasitol. 2014 Feb;30(2):65–74.
   PubMed Web of Science ®Google Scholar
• Alvarenga JS, Ligeiro CM, Gontijo CM, et al. KDNA genetic signatures obtained by LSSP-PCR analysis of Leishmania (Leishmania) infantum isolated from the new and the old world. PLoS One. 2012;7(8):e43363.
   PubMed Web of Science ®Google Scholar
• Matlashewski G, Arana B, Kroeger A, et al. Visceral leishmaniasis: elimination with existing interventions. Lancet Infect Dis. 2011 Apr;11(4):322–325.
   PubMed Web of Science ®Google Scholar
• Khadem F, Uzonna JE. Immunity to visceral leishmaniasis: implications for immunotherapy. Future Microbiol. 2014;9(7):901–915.
   PubMed Web of Science ®Google Scholar
• Ato M, Stäger S, Engwerda CR, et al. Defective CCR7 expression on dendritic cells contributes to the development of visceral leishmaniasis. Nat Immunol. 2002 Dec;3(12):1185–1191.
   PubMed Web of Science ®Google Scholar
• Kaye P, Scott P. Leishmaniasis: complexity at the host-pathogen interface. Nat Rev Microbiol. 2011 Jul 11;9(8):604–615.
   PubMed Web of Science ®Google Scholar
• Liu D, Uzonna JE. The early interaction of Leishmania with macrophages and dendritic cells and its influence on the host immune response. Front Cell Infect Microbiol. 2012 Jun 12;2:83.
   PubMed Web of Science ®Google Scholar
• Flandin JF, Chano F, Descoteaux A. RNA interference reveals a role for TLR2 and TLR3 in the recognition of Leishmania donovani promastigotes by interferon-gamma-primed macrophages. Eur J Immunol. 2006 Feb;36(2):411–420.
   PubMed Web of Science ®Google Scholar
• Mukherjee AK, Gupta G, Adhikari A, et al. Miltefosine triggers a strong proinflammatory cytokine response during visceral leishmaniasis: role of TLR4 and TLR9. Int Immunopharmacol. 2012 Apr;12(4):565–572.
   PubMed Web of Science ®Google Scholar
• Paun A, Bankoti R, Joshi T, et al. Critical role of IRF-5 in the development of T helper 1 responses to Leishmania donovani infection. PLoS Pathog. 2011 Jan 6;7(1):e1001246.
   PubMed Web of Science ®Google Scholar
• Laurenti MD, Orn A, Sinhorini IL, et al. The role of complement in the early phase of Leishmania (Leishmania) amazonensis infection in BALB/c mice. Braz J Med Biol Res. 2004 Mar;37(3):427–434.
   PubMed Web of Science ®Google Scholar
• Wozencraft AO, Blackwell JM. Increased infectivity of stationary-phase promastigotes of Leishmania donovani: correlation with enhanced C3 binding capacity and CR3-mediated attachment to host macrophages. Immunology. 1987 Apr;60(4):559–563.
   PubMed Web of Science ®Google Scholar
• Da Silva RP, Hall BF, Joiner KA, et al. CR1, the C3b receptor, mediates binding of infective Leishmania major metacyclic promastigotes to human macrophages. J Immunol. 1989 Jul 15;143(2):617–622.
   PubMed Web of Science ®Google Scholar
• Talamás-Rohana P, Wright SD, Lennartz MR, et al. Lipophosphoglycan from Leishmania mexicana promastigotes binds to members of the CR3, p150,95 and LFA-1 family of leukocyte integrins. J Immunol. 1990 Jun 15;144(12):4817–4824.
   PubMed Web of Science ®Google Scholar
• Ricardo-Carter C, Favila M, Polando RE, et al. Leishmania major inhibits IL-12 in macrophages by signalling through CR3 (CD11b/CD18) and down-regulation of ETS-mediated transcription. Parasite Immunol. 2013 Dec;35(12):409–420.
   PubMed Web of Science ®Google Scholar
• Guimarães-Costa AB, Nascimento MT, Froment GS, et al. Leishmania amazonensis promastigotes induce and are killed by neutrophil extracellular traps. Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6748–6753.
   PubMed Web of Science ®Google Scholar
• Mendes-Sousa AF, Nascimento AA, Queiroz DC, et al. Different host complement systems and their interactions with saliva from Lutzomyia longipalpis (Diptera, Psychodidae) and Leishmania infantum promastigotes. PLoS One. 2013 Nov 8;8(11):e79787.
   PubMedGoogle Scholar
• Gabriel C, McMaster WR, Girard D, et al. Leishmania donovani promastigotes evade the antimicrobial activity of neutrophil extracellular traps. J Immunol. 2010 Oct 1;185(7):4319–4327.
   PubMed Web of Science ®Google Scholar
• Peters NC, Egen JG, Secundino N, et al. In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies. Science. 2008 Aug 15;321(5891):970–974.
   PubMed Web of Science ®Google Scholar
• Ribeiro-Gomes FL, Peters NC, Debrabant A, et al. Efficient capture of infected neutrophils by dendritic cells in the skin inhibits the early anti-leishmania response. PLoS Pathog. 2012 Feb;8(2):e1002536.
   PubMed Web of Science ®Google Scholar
• Green SJ, Crawford RM, Hockmeyer JT, et al. Leishmania major amastigotes initiate the L-arginine-dependent killing mechanism in IFN-gamma-stimulated macrophages by induction of tumor necrosis factor-alpha. J Immunol. 1990 Dec 15;145(12):4290–4297.
   PubMed Web of Science ®Google Scholar
• Maroof A, Kaye PM. Temporal regulation of interleukin-12p70 (IL-12p70) and IL-12-related cytokines in splenic dendritic cell subsets during Leishmania donovani infection. Infect Immun. 2008 Jan;76(1):239–249. Epub 2007 Nov 12
   PubMed Web of Science ®Google Scholar
• McFarlane E, Perez C, Charmoy M, et al. Neutrophils contribute to development of a protective immune response during onset of infection with Leishmania donovani. Infect Immun. 2008 Feb;76(2):532–541. Epub 2007 Dec 3
   PubMed Web of Science ®Google Scholar
• Maurer M, Lopez Kostka S, Siebenhaar F, et al. Skin mast cells control T cell-dependent host defense in Leishmania major infections. FASEB J. 2006 Dec;20(14):2460–2467.
   PubMed Web of Science ®Google Scholar
• Rai AK, Thakur CP, Singh A, et al. Regulatory T cells suppress T cell activation at the pathologic site of human visceral leishmaniasis. PLoS One. 2012;7(2):e31551.
   PubMed Web of Science ®Google Scholar
• Chowdhury BP, Das S, Majumder S, et al. Immunomodulation of host-protective immune response by regulating Foxp3 expression and Treg function in Leishmania-infected BALB/c mice: critical role of IRF1. Pathog Dis. 2015 Nov;73(8):ftv063. doi:10.1093/femspd/ftv063. Epub 2015 Aug 21.
   PubMed Web of Science ®Google Scholar
• Costa AS, Costa GC, Aquino DM, et al. Cytokines and visceral leishmaniasis: a comparison of plasma cytokine profiles between the clinical forms of visceral leishmaniasis. Mem Inst Oswaldo Cruz. 2012 Sep;107(6):735–739.
   PubMed Web of Science ®Google Scholar
• Kumar R, Singh N, Gautam S, et al. Leishmania specific CD4 T cells release IFNγ that limits parasite replication in patients with visceral leishmaniasis. PLoS Negl Trop Dis. 2014 Oct 2;8(10):e3198.
   PubMedGoogle Scholar
• Nico D, Maran N, Santos L, et al. Expression of leukosialin (CD43) defines a major intrahepatic T cell subset associated with protective responses in visceral leishmaniasis. Parasit Vectors. 2015 Feb 19;8:111.
   PubMedGoogle Scholar
• Gautam S, Kumar R, Maurya R, et al. IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. J Infect Dis. 2011 Oct 1;204(7):1134–1137.
   PubMed Web of Science ®Google Scholar
• Nylén S, Maurya R, Eidsmo L, et al. Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med. 2007 Apr 16;204(4):805–817. Epub 2007 Mar 26.
   PubMed Web of Science ®Google Scholar
• Gautam S, Kumar R, Singh N, et al. CD8 T cell exhaustion in human visceral leishmaniasis. J Infect Dis. 2014 Jan 15;209(2):290–299.
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J. An update on pharmacotherapy for leishmaniasis. Expert Opin Pharmacother. 2015 Feb;16(2):237–252.
   PubMed Web of Science ®Google Scholar
• Rama M, Kumar NV, Balaji S. A comprehensive review of patented antileishmanial agents. Pharm Pat Anal. 2015 Jan;4(1):37–56.
   PubMed Web of Science ®Google Scholar
• Alvar J, Croft S, Olliaro P. Chemotherapy in the treatment and control of leishmaniasis. Adv Parasitol. 2006;61:223–274.
   PubMed Web of Science ®Google Scholar
• Maltezou HC. Drug resistance in visceral leishmaniasis. J Biomed Biotechnol. 2010;2010:617521.
   PubMedGoogle Scholar
• World Health Organization report on global surveillance of epidemic-prone infectious diseases. WHO/CDS/CSR/ISR/2000.1.
   Google Scholar
• Moore EM, Lockwood DN. Treatment of visceral leishmaniasis. J Glob Infect Dis. 2010 May;2(2):151–158.
   PubMedGoogle Scholar
• Mohamed-Ahmed AH, Brocchini S, Croft SL. Recent advances in development of amphotericin B formulations for the treatment of visceral leishmaniasis. Curr Opin Infect Dis. 2012 Dec;25(6):695–702.
   PubMed Web of Science ®Google Scholar
• Ashok P, Lathiya H, Murugesan S. Manzamine alkaloids as antileishmanial agents: a review. Eur J Med Chem. 2015 Jun 5;97:928–936.
   PubMed Web of Science ®Google Scholar
• Roatt BM, Aguiar-Soares RD, Coura-Vital W, et al. Immunotherapy and immunochemotherapy in visceral leishmaniasis: promising treatments for this neglected disease. Front Immunol. 2014 Jun 13;5:272.
   PubMed Web of Science ®Google Scholar
• Asad M, Bhattacharya P, Banerjee A, et al. Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOMETM10, a new liposomal amphotericin B. BMC Infect Dis. 2015 Apr 17;15:188.
   PubMed Web of Science ®Google Scholar
• Dorlo TP, Balasegaram M, Beijnen JH, et al. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment ofleishmaniasis. J Antimicrob Chemother. 2012 Nov;67(11):2576–2597.
   PubMed Web of Science ®Google Scholar
• McGwire BS, Satoskar AR. Leishmaniasis: clinical syndromes and treatment. QJM. 2014 Jan;107(1):7–14.
   PubMed Web of Science ®Google Scholar
• Jha RK, Sah AK, Shah DK, et al. The treatment of visceral leishmaniasis: safety and efficacy. JNMA J Nepal Med Assoc. 2013 OctDec;52(192):645–651.
   PubMedGoogle Scholar
• Pm L, Struchiner CJ, Galvani AP. Modeling transmission dynamics and control of vector-borne neglected tropical diseases. PLoS Negl Trop Dis. 2010 Oct 26;4(10):e761.
   PubMedGoogle Scholar
• Stober CB, Lange UG, Roberts MT, et al. From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine Leishmania major infection. Vaccine. 2006 Mar 24;24(14):2602–2616.
   PubMed Web of Science ®Google Scholar
• John L, John GJ, Kholia T. A reverse vaccinology approach for the identification of potential vaccine candidates from Leishmania spp. Appl Biochem Biotechnol. 2012 Jul;167(5):1340–1350.
   PubMed Web of Science ®Google Scholar
• Lakshmi BS, Wang R, Madhubala R. Leishmania genome analysis and high-throughput immunological screening identifies tuzin as a novel vaccine candidate against visceral leishmaniasis. Vaccine. 2014 Jun 24;32(30):3816–3822.
   PubMed Web of Science ®Google Scholar
• Singh SP, Roopendra K, Mishra BN. Genome-Wide Prediction of Vaccine Candidates for Leishmania major: an Integrated Approach. J Trop Med. 2015;2015:709216.
   PubMedGoogle Scholar
• Palatnik-de-Sousa CB. Vaccines for canine leishmaniasis. Front Immunol. 2012 Apr;17(3):69.
   Google Scholar
• Decuypere S, Vanaerschot M, Brunker K, et al. Molecular mechanisms of drug resistance in natural Leishmania populations vary with genetic background. PLoS Negl Trop Dis. 2012;6(2):e1514.
   PubMedGoogle Scholar
• Mukhopadhyay R, Mukherjee S, Mukherjee B, et al. Characterisation of antimony-resistant Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells. Int J Parasitol. 2011 Nov;41(1314):1311–1321.
   PubMedGoogle Scholar
• Purkait B, Singh R, Wasnik K, et al. Up-regulation of silent information regulator 2 (Sir2) is associated with amphotericin B resistance in clinical isolates of Leishmania donovani. J Antimicrob Chemother. 2015 May;70(5):1343–1356.
   PubMed Web of Science ®Google Scholar
• Singh N, Chatterjee M, Sundar S. The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India. Parasit Vectors. 2014 Dec;17(7):596.
   Google Scholar
• Purkait B, Kumar A, Nandi N, et al. Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani. Antimicrob Agents Chemother. 2012 Feb;56(2):1031–1041.
   PubMed Web of Science ®Google Scholar
• Luque-Ortega JR, De La Torre BG, Hornillos V, et al. Defeating Leishmania resistance to miltefosine (hexadecylphosphocholine) by peptide-mediated drug smuggling: a proof of mechanism for trypanosomatid chemotherapy. J Control Release. 2012 Aug 10;161(3):835–842.
   PubMed Web of Science ®Google Scholar
• Mishra J, Madhubala R, Singh S. Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern. Parasitol Res. 2013 Mar;112(3):1001–1009.
   PubMed Web of Science ®Google Scholar
• Sundar S, Singh A, Singh OP. Strategies to overcome antileishmanial drugs unresponsiveness. J Trop Med. 2014;2014:1–7.
   Google Scholar
• Mukhopadhyay D, Dalton JE, Kaye PM, et al. Post kala-azar dermal leishmaniasis: an unresolved mystery. Trends Parasitol. 2014 Feb;30(2):65–74.
   PubMed Web of Science ®Google Scholar
• Roatt BM, Aguiar-Soares RD, Coura-Vital W, et al. Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: promising Treatments for this Neglected Disease. Front Immunol. 2014 Jun 13;5:272.
   PubMed Web of Science ®Google Scholar
• Zijlstra EE. PKDL and other dermal lesions in HIV co-infected patients with Leishmaniasis: review of clinical presentation in relation to immune responses. PLoS Negl Trop Dis. 2014 Nov 20;8(11):e3258.
   PubMedGoogle Scholar
• Skinner RB Jr. Imiquimod as an immune response modulator in infectious conditions. Postgrad Med. 2002 Dec;112(6 Suppl Using):8–16.
   PubMedGoogle Scholar
• Dasgupta S, Aghazadeh-Dibavar S, Bandyopadyay M. The role of toll-like receptor agonists in the immunotherapy of leishmaniosis. An update and proposal for a new form of anti-leishmanial therapy. Ann Parasitol. 2014;60(2):75–82.
   PubMedGoogle Scholar
• Jain K, Jain NK. Vaccines for visceral leishmaniasis: a review. J Immunol Methods. 2015 Jul;422:1–12.
   PubMed Web of Science ®Google Scholar
• Valenzuela JG, Belkaid Y, Garfield MK, et al. Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein. J Exp Med. 2001 Aug 6;194(3):331–342.
   PubMed Web of Science ®Google Scholar
• Enserink M. Infectious diseases. Sand fly saliva may be key to new vaccine. Science. 2001 Aug 10;293(5532):1028.
   PubMed Web of Science ®Google Scholar
• Collin N, Gomes R, Teixeira C, et al. Sand fly salivary proteins induce strong cellular immunity in a natural reservoir of visceral leishmaniasis with adverse consequences for Leishmania. PLoS Pathog. 2009 May;5(5):e1000441.
   PubMed Web of Science ®Google Scholar
• González U, Pinart M, Sinclair D, et al. Vector and reservoir control for preventing leishmaniasis. Cochrane Database Syst Rev. 2015 Aug 5;8:CD008736.
   PubMedGoogle Scholar